ClinicalTrials.gg
RecruitingNCT07233486DISMAUpdated Nov 18, 2025

A Multicenter, Randomized, Crossover Clinical Trial Study of Digital Intelligence Software in Patients With MAFLD

An interventional study of Digital Intelligence Software Intervention Group in MAFLD, sponsored by The Affiliated Hospital of Hangzhou Normal University. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-11-18.

Sponsored by The Affiliated Hospital of Hangzhou Normal University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Aug 2024, registered Aug 2025).
  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,000
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Cirrhosis associated with metabolic associated fatty liver disease (MAFLD) can lead to a series of adverse outcomes in and outside the liver, but there is no approved treatment so far. In recent years, the prevalence of MAFLD-related cirrhosis in our country is increasing rapidly, but its clinical, pathological characteristics and natural prognosis are not clear, and there is a lack of standardized and effective prevention and treatment strategies.Through"Digital Intelligence software" to assist clinicians in MAFLD patients with remote data intervention, lifestyle intervention guidance and follow-up management, to evaluate the efficacy and safety of the intervention software on body weight and blood glucose in patients with MAFLD.

02

Conditions studied

  • MAFLD
03

In context

Lead sponsor

The Affiliated Hospital of Hangzhou Normal University is the lead sponsor of 11 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult patients aged 18-65 years with a of 24-35 kg/m².
  2. Confirmed diagnosis of Metabolic-associated Fatty Liver Disease (MAFLD), defined by a FibroScan® result > 248 dB/m or an MRI-PDFF > 5%.
  3. Willing and able to provide written and comply with the study protocol, including the use of a compatible smartphone for digital health components.
  4. If treated for Type 2 Diabetes Mellitus (T2DM), must be on a stable medication regimen for at least 3 months prior to baseline (Day 0), with the expectation to maintain stability throughout the study barring medical necessity.
  5. If taking medications with potential NASH-remitting effects (e.g., vitamin E, thiazolidinediones), must be on a stable dose for at least 3 months prior to Day 0.

Exclusion criteria

Exclusion Criteria

  1. Subjects were excluded from participation if they met any of the following criteria, based on the most recent pre-randomization assessments:
  2. Evidence of cirrhosis, defined as histological stage F4 or its clinical equivalent.
  3. History of heavy alcohol consumption (>30 g/day for males, >20 g/day for females) for more than 3 consecutive months within one year prior to screening.
  4. Prior or planned solid organ transplantation (excluding corneal transplants).
  5. Planned bariatric surgery. A history of bariatric surgery was permitted only if weight had been stable (variation \<10%) for at least 3 months prior to screening.
  6. Presence of other chronic liver diseases, including:
  7. surface antigen (HBsAg) positivity.
  8. virus (HCV) RNA positivity.
  9. Primary biliary cholangitis, primary sclerosing cholangitis, hepatitis, or overlap syndromes.
  10. Wilson's disease, alpha-1 antitrypsin deficiency (ZZ phenotype), or hereditary hemochromatosis.
  11. History of Type 1 Diabetes Mellitus. Uncontrolled Type 2 Diabetes Mellitus, defined as >9% or current insulin therapy.
  12. History of hepatic decompensation events (e.g., ascites, hepatic encephalopathy, variceal hemorrhage).
  13. Any of the following laboratory abnormalities at screening:
  14. count \< 150,000/mm³
  15. Albumin \< 3.0 g/dL
  16. (INR) > 1.3
  17. Alkaline Phosphatase (ALP) > 2 × (ULN)
  18. (ALT) or Aspartate Aminotransferase (AST) > 5 × ULN
  19. Total > 1.3 × ULN (except in cases of documented Gilbert's syndrome)
  20. Estimated (eGFR) \< 60 mL/min/1.73 m²
  21. \< 10 g/dL
  22. Uncontrolled thyroid dysfunction, defined as a thyroid-stimulating hormone (TSH) level \< 0.1 or > 10 µIU/mL at screening.
  23. Documented -1 or HIV-2 infection.
  24. Known Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency.
  25. Significant cardiovascular history, including myocardial infarction, unstable angina, heart failure, uncontrolled arrhythmia, coronary artery bypass graft, or percutaneous coronary intervention within one year prior to screening.
  26. Diagnosis of within the past 2 years (except for adequately treated basal cell carcinoma or cutaneous squamous cell carcinoma).
  27. Severe co-morbid respiratory, cardiac, cerebrovascular, hepatic, or renal conditions that, in the investigator's judgment, would preclude safe participation in a diet and exercise intervention.
  28. Active, severe infection requiring parenteral antimicrobial therapy within 30 days of screening.
  29. Major surgery within 30 days prior to screening.
  30. Chronic use of medications known to promote hepatic steatosis (e.g., systemic , amiodarone, methotrexate, tamoxifen, valproic acid) within 3 months of screening. Short-term, low-dose corticosteroid use was permissible.
  31. Current or planned treatment with radiation therapy, cytotoxic chemotherapy, or immunomodulatory agents (e.g., interleukins, interferons).
  32. Treatment with any agent within 6 months prior to screening, or prior participation in a clinical trial for NASH/MAFLD within 6 months.

Pregnancy or lactation.

1.Any other condition or circumstance that, in the opinion of the Investigator, would compromise patient safety or the validity of the study data.

Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
2,000 participants (estimated)

Study arms

  • No intervention
    Life intervention group

    Detailed nutritional intervention protocols were developed according to patients' food preferences, dietary habits, physical activity levels, working conditions, sociocultural conditions, and lifestyle. Low-carbon diet and balanced diet were adopted for dietary intervention. According to the patients' basic metabolic level, overweight and fatty liver degree, a calorie restriction diet was formulated, and it was recommended to reduce 500-1000 kcal calories per day, a balanced diet of pastries and carbohydrates, with increased intake of whole grains, omega-3 fatty acid, and dietary fiber. Choose the right ingredients for your particular patient's diet

  • Placebo comparator
    Digital Intelligence Software Group

    Study participants were guided by the program officer to download and register the"Data Intelligence software (patient-side)" and to establish a relationship with the clinicians involved in the study, baseline data were collected under the guidance of the program director, health records were created, and data were collected using a software-supported"Body composition analyzer.". The participating clinicians evaluated the subjects through the"Digital Intelligence software (doctor side)", and formulated the diet and exercise program according to the individual conditions of the subjects.

    Procedure: Digital Intelligence Software Intervention Group

Interventions

  • ProcedureDigital Intelligence Software Intervention Group

    Study participants were guided by the program officer to download and register the"Data Intelligence software (patient-side)" and to establish a relationship with the clinicians involved in the study, baseline data were collected under the guidance of the program director, health records were created, and data were collected using a software-supported"Body composition analyzer.". The participating clinicians evaluated the subjects through the"Digital Intelligence software (doctor side)", and formulated the diet and exercise program according to the individual conditions of the subjects.

06

What researchers measure

Primary outcomes

  1. Body weight

    Absolute and relative changes from baseline in body weight

    Time frame: 48weeks

Secondary outcomes

  1. Fasting plasma glucose

    Compare the changes in fasting blood glucose before and after treatment

    Time frame: 48week

  2. Liver MRI PDFF

    To evaluate the effects of weight and glucose reduction interventions on proton density fat fraction (MRI-PDFF) in patients with MAFLD

    Time frame: 48weeks

  3. Liver FibroScan

    liver fat attenuation parameter (CAP) , liver stiffness value (LSM)

    Time frame: 48week

  4. Body Mass Index (BMI)

    Clarify how multiple measurements will be aggregated to arrive at one reported value weight and height will be combined to report BMI in kg/m\^2)

    Time frame: 48week

Other outcomes

  1. Biochemical indicators

    Serum levels of aspartate aminotransferase (AST U/L) and alanine aminotransferase (ALT U/L)

    Time frame: 48week

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — The study has not been completed

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2024 (actual). Primary completion is estimated for Jul 2027, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2025
First posted
Nov 18, 2025
StartActual
Aug 1, 2024
Primary completionEst.
Jul 30, 2027
CompletionEst.
Aug 30, 2028
Last update
Nov 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07233486
Lead sponsor
The Affiliated Hospital of Hangzhou Normal University
Responsible party
Sponsor
First posted
Nov 18, 2025
Start date
Aug 1, 2024
Primary completion
Jul 30, 2027 (estimated)
Completion
Aug 30, 2028 (estimated)
Last update
Nov 18, 2025

Study contacts

junping shi, doctor's degree
Contact
20131004@hznu.edu.cn
+86 139 5712 1199

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion